tirzepatide trial reduces albuminuria among adults with type 2 diabetes in SURPASS trials Weight-loss jab Mounjaro trial begins

"Some can maintain on a lower dose, while others require ongoing therapy at their current dose." If you're like me and squeamish about the prospect of weekly injections indefinitely, take note that oral GLP-1s are now on the market: the Food and Drug Administration (FDA) approved oral Wegovy in December 2025 and Foundayo (orforglipron) in April 2026

[6] Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury

We conduct several quality assurance tests on our products and are an excellent pharmaceutical institution overall

For example, if a patient experiences increased gastrointestinal side effects from a GLP-1 agonist while on hormonal therapy, adjustments may be necessary to optimise comfort and therapeutic outcomes

On the flip side, recent studies show that GLP-1 medications may decrease a persons risk for cardiovascular disease and dementia